From DCAT Value Chain Insights (VCI)
Valeant Pharmaceuticals International, Inc. has appointed Robert L. Rosiello as Executive Vice President and will take over the role of Chief Financial Officer from Howard Schiller on July 1, 2015. Mr. Schiller will remain on Valeant's Board and is expected to serve as a consultant to Valeant.
Mr. Rosiello worked 30 years at McKinsey & Company helping healthcare, technology and consumer companies deliver growth through M&A and business unit financial performance improvement. As Senior Partner in charge of the global merger practice for the past decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S., Europe and Asia.
Source: Valeant Pharmaceuticals
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription